Financial Performance - The company's revenue for Q3 2021 reached ¥291,233,395.74, representing a year-on-year increase of 21.86%[3] - Net profit attributable to shareholders was ¥42,096,142.37, up 17.42% compared to the same period last year[3] - The basic earnings per share (EPS) increased to ¥0.3693, reflecting an 18.37% growth year-on-year[3] - Operating income for the year-to-date period was ¥745,264,628.80, a significant increase of 37.54% driven by higher sales of gynecological products[8] - The net profit for the third quarter of 2021 was CNY 88,933,462.49, representing an increase of 45.9% compared to CNY 61,056,054.17 in the same period last year[19] - The total comprehensive income attributable to the parent company was CNY 88,933,462.49, up from CNY 61,056,054.17, marking a 45.9% increase[20] - The company reported a total operating profit of CNY 101,463,975.16, which is an increase from CNY 70,558,767.01 in the same quarter last year[19] - The total revenue from sales of goods and services received was CNY 730,647,546.59, compared to CNY 562,219,123.37 in the previous year, reflecting a growth of 30%[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,553,224,196.03, a 1.13% increase from the end of the previous year[4] - The total assets of the company as of September 30, 2021, were RMB 1,553,224,196.03, slightly up from RMB 1,535,933,766.56 at the end of 2020[17] - The total liabilities decreased to RMB 660,544,340.81 from RMB 707,636,495.11, indicating a reduction of 6.7%[16] - Total liabilities reached approximately ¥715.28 million, with current liabilities at ¥513.64 million and non-current liabilities at ¥201.64 million[27] - The company's equity attributable to shareholders rose to ¥892,679,855.22, marking a 7.77% increase from the previous year[4] - The company's equity totaled approximately ¥828.30 million, with retained earnings of ¥341.07 million[27] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥97,683,353.15, showing a slight decrease of 2.69%[3] - Cash flow from operating activities generated a net amount of CNY 97,683,353.15, slightly down from CNY 100,384,660.05 in the previous year[21] - Total cash inflow from investment activities was CNY 425,180,124.83, compared to CNY 203,885,507.08 in the prior year, indicating a significant increase of 108.5%[22] - The net cash flow from investment activities was negative at CNY -198,550,274.06, an improvement from CNY -300,483,444.24 in the same period last year[22] - Cash flow from financing activities resulted in a net outflow of CNY -130,936,122.11, compared to a net inflow of CNY 245,757,737.78 in the previous year[22] Research and Development - Research and development expenses surged by 111.62% to ¥11,714,744.33, indicating increased investment in innovation[9] - Research and development expenses increased to RMB 11,714,744.33, up from RMB 5,535,848.58, marking a growth of 111.5% year-on-year[17] Inventory and Receivables - The company reported a 42.80% increase in accounts receivable, totaling ¥255,336,062.94, primarily due to sales growth[8] - Accounts receivable increased significantly to RMB 255,336,062.94, compared to RMB 178,806,442.88 at the end of 2020, reflecting a growth of 42.8%[14] - The inventory level rose to RMB 91,524,859.77 from RMB 86,821,180.60, reflecting an increase of 5.5%[15] Other Financial Information - The company's cash and cash equivalents decreased to RMB 98,284,359.97 from RMB 330,087,402.99 at the end of 2020, representing a decline of 70.2%[14] - The weighted average return on equity was 4.91%, reflecting a 0.26% increase compared to the previous year[4] - The company's net profit for the period was impacted by credit impairment losses of RMB -3,635,322.39, compared to RMB -1,541,064.86 in the previous year[17] - The company plans to continue expanding its market presence and investing in new technologies to enhance its product offerings and operational efficiency[23] - The company has not undergone an audit for the third quarter report[28] - The report indicates a significant increase in total liabilities compared to the previous period, reflecting a rise of approximately ¥7.64 million[27] - The company is implementing new leasing standards, which may affect future financial reporting[28]
新天药业(002873) - 2021 Q3 - 季度财报